Arcus Biosciences (RCUS) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
H.C. Wainwright Upgrades Arcus Biosciences (RCUS) to Buy
February 26, 2025 6:06 AM ESTH.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (NYSE: RCUS) from Neutral to Buy with a price target of $24.00.
The analyst comments "Initial cas + cabo data expected in mid-2025; we are increasingly positive on opportunity given cas efficacy vs belzutifan. The ARC-20 study evaluating casdatifan (cas) monotherapy and in combo with other agents in clear cell renal cell carcinoma (ccRCC) has enrolled ~40 patients in the cas + cabozantinib (cabo) cohort, which is meant to evaluate the same combo and patient population as the Phase 3 PEAK-1 study expected to initiate in 2Q25... More
